Research Project
Grant-in-Aid for Young Scientists (B)
In this study we explored the efficacy of a AKT-mTOR pathway inhibitor for docetaxel resistant prostate cancer cell line: C4-2AT6. C4-2AT6 cells revealed combined administration of AKT-mTOR pathway inhibitor and docetaxel had a significant and synergistic
All 2013 2012
All Presentation (11 results)